Transcode Therapeutics Enters Material Definitive Agreement
Ticker: RNAZ · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1829635
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Transcode Therapeutics just signed a big deal, details TBD.
AI Summary
On September 30, 2025, Transcode Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signifies a potentially significant development for Transcode Therapeutics, Inc., which could impact its business operations, strategic direction, or financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty and potential risk.
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40363 (other) — Commission File Number
- 81-1065054 (other) — I.R.S. Employer Identification No.
- 6 Liberty Square, #2382 Boston, Massachusetts 02109 (address) — Address of principal executive offices
- 857-837-3099 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Transcode Therapeutics, Inc.?
The filing states that Transcode Therapeutics, Inc. entered into a material definitive agreement on September 30, 2025, but does not provide specific details about the agreement itself.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the counterparty to the material definitive agreement.
What are the key terms and financial implications of this agreement?
The filing does not specify the key terms or financial implications of the material definitive agreement.
When was the material definitive agreement officially entered into?
The material definitive agreement was entered into on September 30, 2025.
Does this agreement represent a significant shift in Transcode Therapeutics' business strategy?
While the filing categorizes the agreement as 'material definitive,' it does not provide enough information to determine if it represents a significant shift in the company's strategy.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2025-10-03 16:15:32
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital
- $1,550,000 — n certain milestones was increased from $1,550,000 to $2,950,000 for each patent family; a
- $2,950,000 — stones was increased from $1,550,000 to $2,950,000 for each patent family; and the individ
Filing Documents
- tm2527978d1_8k.htm (8-K) — 23KB
- 0001104659-25-096658.txt ( ) — 187KB
- rnaz-20250930.xsd (EX-101.SCH) — 3KB
- rnaz-20250930_lab.xml (EX-101.LAB) — 33KB
- rnaz-20250930_pre.xml (EX-101.PRE) — 22KB
- tm2527978d1_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry into a Material Definitive Agreement. On September 30, 2025, TransCode Therapeutics, Inc. (the "Company") and The General Hospital Corporation d/b/a Massachusetts General Hospital (the "Licensor") entered into the Second Amendment to Exclusive Patent License Agreement (the "Second Amendment") to that certain Exclusive Patent License Agreement, dated October 26, 2018, and amended by the First Amendment to Exclusive Patent License Agreement, dated October 30, 2020, (as so amended, the "MGH License"). Pursuant to the Second Amendment, effective August 15, 2025, the timelines for the pre-sales requirements for Patent Family 1 (as defined in the MGH License) were updated, and the requirements and timelines for the pre-sales requirements for Patent Family 2 (as defined in the MGH License) were updated. In addition, the aggregate dollar amount of one-time milestone payments the Company shall pay the Licensor upon certain milestones was increased from $1,550,000 to $2,950,000 for each patent family; and the individual amounts for therapeutic product- or processes-related milestone payments were updated. The foregoing description of the Second Amendment does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of the Second Amendment, which will be filed with the Securities and Exchange Commission as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2025 TransCode Therapeutics, Inc. By: /s/ Thomas A. Fitzgerald Thomas A. Fitzgerald Interim Chief Executive Officer; Chief Financial Officer